Advancing precision immunotherapy through next generation sequencing of T-cell receptors: Part II

Sponsored by: Thermo Fisher Scientific - Ion Torrent

Speaker

Timothy Looney, PhD

Staff Scientist, Bioinformatics, Thermo Fisher Scientific
BIOGRAPHY

Event Date & Time

DATE: September 12, 2018

TIME: 08:00am PDT, 11:00am EDT

Abstract

Immuno-Oncology Webinar Series (#3 of 3)

In the final presentation of this webinar series, we will continue our discussions of recent advancements in the application of next-generation sequencing of T cell receptor beta (TCRB) chain repertoires to precision immunotherapy. Last month, Dr. Looney highlighted novel applications of long-amplicon TCRB sequencing. This month we introduce a newly launched short-amplicon TCRB sequencing assay designed to interrogate the TCRB CDR3 region from fresh or formalin-fixed paraffin-embedded (FFPE) samples. Dr. Looney will present data suggesting that short-amplicon TCRB repertoire sequencing of FFPE samples may be used to characterize T cell responses to tumor antigens through the assessment of T cell expansion, diversity and receptor convergence. Additionally, short-read sequencing of the peripheral blood may enable detection of low frequency malignant T cell clones for future minimal residual disease (MRD) monitoring applications.

Learning Objectives:

Understand new applications of T cell receptor sequencing to immunotherapy translational research.
Describe the advantages of short-amplicon TCRB sequencing via Ion Torrent for characterization of the tumor microenvironment

Register for our 3 Part Series here:

#1 - Deciphering the cancer immunity cycle through next generation sequencing
#2 - Advancing precision immunotherapy through next-generation sequencing of T cell receptors: Part I
#3 - Advancing precision immunotherapy through next generation sequencing of T-cell receptors: Part II

Advancing precision immunotherapy through next generation sequencing of T-cell receptors: Part II

Advancing precision immunotherapy through next generation sequencing of T-cell receptors: Part II

Timothy Looney, PhD

Advancing precision immunotherapy through next generation sequencing of T-cell receptors: Part II